Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2018
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2018
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD137 is a member of the tumor necrosis factor (TNF) receptor family. CD137 is expressed by activated T cells (but to a larger extent on CD8 than on CD4 T cells). CD137 are involved in the regulation of a wide range of immune activities.
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 28 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 17 and 4 respectively. Similarly, the universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Metastatic Cancer, Metastatic Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Mantle Cell Lymphoma, Metastatic Breast Cancer, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Thyroid Cancer, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Esophageal Cancer, Gliosarcoma, Lung Cancer, Lymphoma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Nasopharyngeal Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Primary CNS Lymphoma, Primary Mediastinal B-Cell Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Sarcomas, Small-Cell Lung Cancer and Thymoma (Thymic Epithelial Tumor).
The latest report Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD137 is a member of the tumor necrosis factor (TNF) receptor family. CD137 is expressed by activated T cells (but to a larger extent on CD8 than on CD4 T cells). CD137 are involved in the regulation of a wide range of immune activities.
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 28 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 17 and 4 respectively. Similarly, the universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Metastatic Cancer, Metastatic Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Mantle Cell Lymphoma, Metastatic Breast Cancer, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Thyroid Cancer, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Esophageal Cancer, Gliosarcoma, Lung Cancer, Lymphoma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Nasopharyngeal Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Primary CNS Lymphoma, Primary Mediastinal B-Cell Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Sarcomas, Small-Cell Lung Cancer and Thymoma (Thymic Epithelial Tumor).
The latest report Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development
Agenus Inc
Alligator Bioscience AB
Apogenix AG
Bicycle Therapeutics Ltd
BioInvent International AB
BioNTech AG
Bristol-Myers Squibb Co
Eli Lilly and Co
Juno Therapeutics Inc
KAHR medical Ltd
LeadArtis SL
MacroGenics Inc
Molecular Partners AG
Pfizer Inc
Pieris Pharmaceuticals Inc
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles
ABP-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aptamer to Antagonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATOR-1016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATOR-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Agonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Agonize CD40 and 4-1BB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target EphA2 and CD137 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD137L for Nasopharyngeal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EU-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize CD137 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISAS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAHR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAHR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lisocabtagene maraleucel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize 41BB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target HER2 and CD137 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize TNFRSF9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CD137 and IL2R for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-342 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-333 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ultra-41BBL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
urelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
utomilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2017: Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH
Dec 11, 2017: Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Dec 09, 2017: Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL
Nov 09, 2017: Molecular Partners Expands and Advances Robust Pipeline of DARPin Therapies in Oncology and Ophthalmology
Nov 01, 2017: Juno Therapeutics to Showcase Promising Data from JCAR-017 Product Development Program at ASH Conference
Oct 24, 2017: Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527
Oct 24, 2017: Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 - a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics
Oct 12, 2017: Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
Oct 02, 2017: Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343
Aug 17, 2017: Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527
Jun 17, 2017: Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma
Jun 12, 2017: Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development
Jun 05, 2017: Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma
May 17, 2017: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 at the 2017 American Society of Clinical Oncology Annual Meeting
May 09, 2017: First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development
Agenus Inc
Alligator Bioscience AB
Apogenix AG
Bicycle Therapeutics Ltd
BioInvent International AB
BioNTech AG
Bristol-Myers Squibb Co
Eli Lilly and Co
Juno Therapeutics Inc
KAHR medical Ltd
LeadArtis SL
MacroGenics Inc
Molecular Partners AG
Pfizer Inc
Pieris Pharmaceuticals Inc
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles
ABP-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aptamer to Antagonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATOR-1016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATOR-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Agonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Agonize CD40 and 4-1BB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target EphA2 and CD137 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD137L for Nasopharyngeal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EU-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize CD137 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISAS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAHR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAHR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lisocabtagene maraleucel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize 41BB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target HER2 and CD137 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize TNFRSF9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CD137 and IL2R for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-342 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-333 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize CD137 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ultra-41BBL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
urelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
utomilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2017: Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH
Dec 11, 2017: Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Dec 09, 2017: Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL
Nov 09, 2017: Molecular Partners Expands and Advances Robust Pipeline of DARPin Therapies in Oncology and Ophthalmology
Nov 01, 2017: Juno Therapeutics to Showcase Promising Data from JCAR-017 Product Development Program at ASH Conference
Oct 24, 2017: Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527
Oct 24, 2017: Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 - a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics
Oct 12, 2017: Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
Oct 02, 2017: Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343
Aug 17, 2017: Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527
Jun 17, 2017: Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma
Jun 12, 2017: Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development
Jun 05, 2017: Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma
May 17, 2017: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 at the 2017 American Society of Clinical Oncology Annual Meeting
May 09, 2017: First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Agenus Inc, H1 2018
Pipeline by Alligator Bioscience AB, H1 2018
Pipeline by Apogenix AG, H1 2018
Pipeline by Bicycle Therapeutics Ltd, H1 2018
Pipeline by BioInvent International AB, H1 2018
Pipeline by BioNTech AG, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Juno Therapeutics Inc, H1 2018
Pipeline by KAHR medical Ltd, H1 2018
Pipeline by LeadArtis SL, H1 2018
Pipeline by MacroGenics Inc, H1 2018
Pipeline by Molecular Partners AG, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Pieris Pharmaceuticals Inc, H1 2018
Dormant Projects, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Agenus Inc, H1 2018
Pipeline by Alligator Bioscience AB, H1 2018
Pipeline by Apogenix AG, H1 2018
Pipeline by Bicycle Therapeutics Ltd, H1 2018
Pipeline by BioInvent International AB, H1 2018
Pipeline by BioNTech AG, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Juno Therapeutics Inc, H1 2018
Pipeline by KAHR medical Ltd, H1 2018
Pipeline by LeadArtis SL, H1 2018
Pipeline by MacroGenics Inc, H1 2018
Pipeline by Molecular Partners AG, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Pieris Pharmaceuticals Inc, H1 2018
Dormant Projects, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Agenus Inc
Alligator Bioscience AB
Apogenix AG
Bicycle Therapeutics Ltd
BioInvent International AB
BioNTech AG
Bristol-Myers Squibb Co
Eli Lilly and Co
Juno Therapeutics Inc
KAHR medical Ltd
LeadArtis SL
MacroGenics Inc
Molecular Partners AG
Pfizer Inc
Pieris Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Agenus Inc
Alligator Bioscience AB
Apogenix AG
Bicycle Therapeutics Ltd
BioInvent International AB
BioNTech AG
Bristol-Myers Squibb Co
Eli Lilly and Co
Juno Therapeutics Inc
KAHR medical Ltd
LeadArtis SL
MacroGenics Inc
Molecular Partners AG
Pfizer Inc
Pieris Pharmaceuticals Inc
